Comparative efficacy and cost effectiveness of splenectomy and thrombopoietin prior to peginterferon and ribavirin therapy with compensatory cirrhosis associated with hepatitis C and thrombocytopenia

Li,Bing; Ji,Ying Jie; Shao,Qing; Zhu,Zhenyu; Ji,Dong; Li,Fan; Chen,Guofeng

doi:10.3892/etm.2015.2830

Comparative efficacy and cost effectiveness of splenectomy and thrombopoietin prior to peginterferon and ribavirin therapy with compensatory cirrhosis associated with hepatitis C and thrombocytopenia

Authors:
- Bing Li
- Ying Jie Ji
- Qing Shao
- Zhenyu Zhu
- Dong Ji
- Fan Li
- Guofeng Chen
View Affiliations

Affiliations: Liver Fibrosis Diagnosis and Treatment Center, 302 Hospital of PLA, Beijing 100039, P.R. China, Liver Disease Center for Military Staff, 302 Hospital of PLA, Beijing 100039, P.R. China, Hepatobiliary Surgery Center, 302 Hospital of PLA, Beijing 100039, P.R. China
Published online on: October 23, 2015 https://doi.org/10.3892/etm.2015.2830
Pages: 2180-2186

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate and compare the treatment efficacy and cost of two therapies, splenectomy and thrombopoietin, in order to optimize the treatment plans for patients with HCV‑associated cirrhosis. A prospective randomized controlled trial was conducted on 69 patients with a platelet count <60,000/mm3 that were enrolled between 2009 and 2013, including 38 cases as the research group and 31 cases as the observed group. The study included two stages: A 4‑week initial treatment and a 48‑week antiviral treatment, during which a number of parameters were evaluated, including platelet count, liver stiffness measure, albumin, total bilirubin, alanine aminotranferase and treatment cost‑effectiveness. Of the 38 patients, 21 underwent a splenectomy and their platelet counts increased to 60,000/mm3 after the 4‑week initial treatment. The patients then started a 48‑week P‑R antiviral treatment, and 18 cases completed the treatment. In addition, 17/38 patients received thrombopoietin as a drug therapy. The platelet counts in 15 cases increased to >60,000/mm3 and the patients received antiviral treatment, among which 9 cases completed the second treatment stage. The expense of the splenectomy group treatment was higher compared with that received by the thrombopoietin group. The results of the present study indicated that splenectomy was more effective at increasing platelet count. More splenectomy patients completed the full course of antiviral treatment and presented a sustained virologic response, compared with the thrombopoietin group. Therefore, splenectomy may be more expensive compared with thrombopoietin; however, the improved efficacy suggests that on balance it is the preferable treatment option.

View Figures

View References

1	Bashour FN, Teran JC and Mullen KD: Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol. 95:2936–2939. 2000. View Article : Google Scholar : PubMed/NCBI
2	Peck-Radosavljevic M: Thrombocytopenia in liver disease. Can J Gastroenterol. 14(Suppl D): 60D–66D. 2000.PubMed/NCBI
3	Giannini EG: Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 23:1055–1065. 2006. View Article : Google Scholar : PubMed/NCBI
4	Moreno A, Bárcena R, Blázquez J, Quereda C, Gil-Grande L, Sánchez J, Moreno L, Perez-Elías MJ, Antela A, Moreno J, et al: Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin. Antivir Ther. 9:1027–1030. 2004.PubMed/NCBI
5	de Oliveira AC: Treatment options in the management of thrombocytopenia in patients infected with HCV. Braz J Infect Dis. 11(Suppl 1): 71–72. 2007. View Article : Google Scholar
6	Fried MW, Shiffman ML, Reddy KL, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:975–982. 2002. View Article : Google Scholar : PubMed/NCBI
7	Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M and Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 358:958–965. 2001. View Article : Google Scholar : PubMed/NCBI
8	Bussel JB and Marks KM: How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection? Nat Clin Pract Gastroenterol Hepatol. 5:424–425. 2008. View Article : Google Scholar : PubMed/NCBI
9	Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D and Burroughs AK: Systematic review: The model for end-stage liver disease - should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 22:1079–1089. 2005. View Article : Google Scholar : PubMed/NCBI
10	Lackner C, Struber G, Bankuti C, Bauer B and Stauber RE: Noninvasive diagnosis of cirrhosis in chronic hepatitis C based on standard laboratory tests. Hepatology. 43:378–379. 2006. View Article : Google Scholar : PubMed/NCBI
11	McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, et al: TPL102357 Study Group: Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 357:2227–2236. 2007. View Article : Google Scholar : PubMed/NCBI
12	O'Brien PC and Fleming TR: A multiple testing procedure for clinical trials. Biometrics. 35:549–556. 1979. View Article : Google Scholar : PubMed/NCBI
13	Manns M, Wedemeyer H and Cornberg M: Treating viral hepatitis C: Efficacy, side effects and complications. Gut. 55:1350–1359. 2006. View Article : Google Scholar : PubMed/NCBI
14	Gutfreund K and Bain V: Chronic viral hepatitis C: Management update. CMAJ. 162:827–833. 2000.PubMed/NCBI
15	Ikezawa K, Naito M, Yumiba T, Iwahashi K, Onishi Y, Kita H, Nishio A, Kanno T, Matsuura T, Ono A, et al: Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection. J Viral Hepat. 17:488–492. 2010.PubMed/NCBI
16	Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr and Crowther MA: American Society of Hematology: The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 117:4190–4207. 2011. View Article : Google Scholar : PubMed/NCBI
17	Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al: International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 115:168–186. 2010. View Article : Google Scholar : PubMed/NCBI
18	Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K and Jun S: A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 118:28–36. 2011. View Article : Google Scholar : PubMed/NCBI
19	Tiede MP, Ahn ER, Jy W, Scagnelli T, Bidot CJ, Horstman LL, Jimenez JJ and Ahn YS: Life-threatening hypercoagulable state following splenectomy in ITP: Successful management with aggressive antithrombotic therapy and danazol. Clin Appl Thromb Hemost. 11:347–352. 2005. View Article : Google Scholar : PubMed/NCBI
20	Crary S and Buchanan G: Vascular complications after splenectomy for hematologic disorders. Blood. 114:2861–2868. 2009. View Article : Google Scholar : PubMed/NCBI
21	Blanchette V and Bolton-Maggs P: Childhood immune thrombocytopenic purpura: Diagnosis and management. Hematol Oncol Clin North Am. 24:249–273. 2010. View Article : Google Scholar : PubMed/NCBI
22	Deutsch VR and Tomer A: Megakaryocyte development and platelet production. Br J Haemotol. 134:453–466. 2006. View Article : Google Scholar
23	Temel T, Cansu DU, Temel HE and Ozakyol AH: Serum thrombopoietin levels and its relationship with thrombocytopenia in patients with cirrhosis. Hepat Mon. 14:e185562014. View Article : Google Scholar : PubMed/NCBI
24	Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K and Yang AS: A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol. 5:712012. View Article : Google Scholar : PubMed/NCBI